The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along with the launch of upcoming therapies and the increasing prevalence of the disease. With the launch of these therapies, many new players are expected to enter the ATTR market space.
LAS VEGAS, Jan. 24, 2024 /PRNewswire/ -- DelveInsight's Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, transthyretin amyloidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Transthyretin Amyloidosis Market Report
- According to DelveInsight's analysis, the market size for ATTR across the 7MM is expected to grow with a significant CAGR by 2032.
- DelveInsight's analysis reveals that the overall diagnosed prevalent population of hATTR in the 7MM was reported as ~15K in 2022.
- Leading transthyretin amyloidosis companies such as Attralus, Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., AstraZeneca, Alexion Pharmaceuticals, Inc., Novo Nordisk A/S, Eidos Therapeutics, and others are developing novel ATTR drugs that can be available in the ATTR market in the coming years.
- The promising transthyretin amyloidosis therapies in the pipeline include I 124-Evuzamitide, Vutrisiran, Eplontersen, Patisiran, ALXN2220, NNC6019-0001, Acoramidis (AG10), and others.
Discover which therapies are expected to grab the major ATTR market share @ Transthyretin Amyloidosis Market Report
Transthyretin Amyloidosis Overview
Transthyretin Amyloidosis (ATTR) is an rare genetic disorder marked by the accumulation of abnormal amyloid protein deposits, categorized into two primary types: hereditary ATTR (hATTR) and wild-type ATTR (wtATTR). hATTR results from inherited mutations in the TTR gene, while wtATTR affects individuals without identified genetic mutations and is more commonly linked to aging. Managing Transthyretin Amyloidosis poses various challenges, including its frequent underdiagnosis or misdiagnosis due to its rarity and the diverse range of symptoms, leading to a delayed initiation of appropriate treatment. Crafting tailored treatment plans for individual patients is intricate due to the heterogeneity of the disease. Diagnosing ATTR amyloidosis typically involves a blend of clinical assessment, genetic testing to pinpoint TTR mutations, and imaging studies like cardiac MRI or nuclear scintigraphy to evaluate organ involvement and amyloid deposition.
Transthyretin Amyloidosis Epidemiology Segmentation
The ATTR epidemiology section provides insights into the historical and current ATTR patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The ATTR market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Diagnosed Prevalent Population of Transthyretin Amyloidosis
- Type-specific Diagnosed Prevalent Cases of Transthyretin Amyloidosis
- Type-specific Diagnosed Prevalent Population of Hereditary Transthyretin Amyloidosis